Tuesday, October 25, 2022 10:18:23 AM
Dennis,
You dont submit a late-breaking abstract to CTAD, the worlds largest and well attended ALZ conference in the world, with just mediocre results. Also, the FDA requiring Anavex to run another P3 trial is the most ridiculous thing circulating. 2-73 is in multiple trials.....Rett, Alz, PDD and has proven to be very safe and effective with almost 90% of patients in all the trials opting for trial extension. . If they beat Biogens Alz drug, which isnt hard to do, it will be approved. Using DNA to find certain DNA that super-responders and responders have in common, the power of the trial doesn't need to be huge like in the past. Those that claim that are about 10 years behind in their thinking, or just trying to spread BS.
As far as NW Bio goes, I suspect application in UK to market DCVax has already been done. Is the ink drying???? Probably.
-Fireman
You dont submit a late-breaking abstract to CTAD, the worlds largest and well attended ALZ conference in the world, with just mediocre results. Also, the FDA requiring Anavex to run another P3 trial is the most ridiculous thing circulating. 2-73 is in multiple trials.....Rett, Alz, PDD and has proven to be very safe and effective with almost 90% of patients in all the trials opting for trial extension. . If they beat Biogens Alz drug, which isnt hard to do, it will be approved. Using DNA to find certain DNA that super-responders and responders have in common, the power of the trial doesn't need to be huge like in the past. Those that claim that are about 10 years behind in their thinking, or just trying to spread BS.
As far as NW Bio goes, I suspect application in UK to market DCVax has already been done. Is the ink drying???? Probably.
-Fireman
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
